Skip to main content
Erschienen in: Indian Journal of Gastroenterology 4/2014

01.07.2014 | Original Article

ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension

verfasst von: Ashish Goel, P. L. Alagammai, Sukesh C. Nair, Ian Mackie, Banumathi Ramakrishna, Jayaprakash Muliyil, Shyamkumar N. Keshava, C. E. Eapen, Elwyn Elias

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

We have reported A disintegrin and metalloprotease with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency in noncirrhotic intrahepatic portal hypertension (NCIPH) patients of European origin with preserved liver function. We aimed to study ADAMTS13–von Willebrand factor (vWF) imbalance in Indian patients with NCIPH.

Methods

Twenty-nine cases with NCIPH [22 males; 29 years (13–58); Child’s A, 23; B, 6], 22 disease controls with cryptogenic chronic liver disease [15 males; 46 years (18–74); Child’s A, 9; B, 9; C, 4] and 17 healthy controls [14 males; 32 years (27–45)] were enrolled in the study. We measured ADAMTS13 antigen and activity (by collagen binding assay (CBA) and by fluorescence resonance energy transfer [FRET] assay), and vWF antigen levels in plasma of study patients.

Results

ADAMTS13 activity by CBA in NCIPH patients (32 %, 5 % to 100 %; median, range; p-value <0.001) and disease controls (36 %, 5 % to 144 %; p = 0.001) was significantly lower than in healthy controls (87 %; 60 % to 148 %). ADAMTS13 antigen and activity by FRET assay were also lower in cases and disease controls. ADAMTS13 activity (by CBA) to antigen ratio was lower in NCIPH and disease controls than in healthy controls. Of 29 NCIPH patients, 3 (all in Child’s A) had severe ADAMTS13 deficiency (<10 % ADAMTS13 activity), and 8 (Child’s A, 7; B, 1) had moderate ADAMTS13 deficiency (10 % to 25 % activity). Conversely, vWF antigen and vWF:ADAMTS13 ratio were higher in patients with NCIPH and in disease controls than in healthy controls.

Conclusions

This study validates the finding of ADAMTS13 deficiency in NCIPH despite preserved liver functions in an Indian population suggesting its involvement in pathogenesis of NCIPH.
Literatur
1.
Zurück zum Zitat Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238–47.PubMed Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238–47.PubMed
2.
Zurück zum Zitat Madhu K, Ramakrishna B, Zachariah U, Eapen CE, Kurian G. Non-cirrhotic intrahepatic portal hypertension. Gut. 2008;57:1529.PubMedCrossRef Madhu K, Ramakrishna B, Zachariah U, Eapen CE, Kurian G. Non-cirrhotic intrahepatic portal hypertension. Gut. 2008;57:1529.PubMedCrossRef
3.
Zurück zum Zitat Tsuneyama K, Kouda W, Nakanuma Y. Portal and parenchymal alterations of the liver in idiopathic portal hypertension: a histological and immunochemical study. Pathol Res Pract. 2002;198:597–603.PubMedCrossRef Tsuneyama K, Kouda W, Nakanuma Y. Portal and parenchymal alterations of the liver in idiopathic portal hypertension: a histological and immunochemical study. Pathol Res Pract. 2002;198:597–603.PubMedCrossRef
4.
Zurück zum Zitat Okuda K. Non-cirrhotic portal hypertension: why is it so common in India? J Gastroenterol Hepatol. 2002;17:1–5.PubMedCrossRef Okuda K. Non-cirrhotic portal hypertension: why is it so common in India? J Gastroenterol Hepatol. 2002;17:1–5.PubMedCrossRef
5.
Zurück zum Zitat Goel A, Madhu K, Zachariah U, et al. A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India. Indian J Med Res. 2013;137:922–7.PubMedCentralPubMed Goel A, Madhu K, Zachariah U, et al. A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India. Indian J Med Res. 2013;137:922–7.PubMedCentralPubMed
6.
Zurück zum Zitat Goel A, Ramakrishna B, Madhu K, et al. Idiopathic noncirrhotic intrahepatic portal hypertension is an ongoing problem in India. Hepatology. 2011;54:2274.PubMedCrossRef Goel A, Ramakrishna B, Madhu K, et al. Idiopathic noncirrhotic intrahepatic portal hypertension is an ongoing problem in India. Hepatology. 2011;54:2274.PubMedCrossRef
7.
Zurück zum Zitat Madhu K, Avinash B, Ramakrishna B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol. 2009;28:83–7.PubMedCrossRef Madhu K, Avinash B, Ramakrishna B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol. 2009;28:83–7.PubMedCrossRef
8.
9.
Zurück zum Zitat Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood. 2002;100:778–85.PubMedCrossRef Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood. 2002;100:778–85.PubMedCrossRef
10.
Zurück zum Zitat Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56:1439–47.PubMedCrossRef Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56:1439–47.PubMedCrossRef
11.
Zurück zum Zitat Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61.PubMedCrossRef Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61.PubMedCrossRef
12.
Zurück zum Zitat Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019–29.PubMed Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019–29.PubMed
13.
Zurück zum Zitat Mackie I, Eapen CE, Neil D, et al. Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 deficiency. Dig Dis Sci. 2013;56:2456–65.CrossRef Mackie I, Eapen CE, Neil D, et al. Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 deficiency. Dig Dis Sci. 2013;56:2456–65.CrossRef
14.
Zurück zum Zitat Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;51:275–80.PubMedCentralPubMedCrossRef Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;51:275–80.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Das NK, Sengupta SR. Arsenicosis: diagnosis and treatment. Indian J Dermatol Venereol Leprol. 2008;74:571–81.PubMedCrossRef Das NK, Sengupta SR. Arsenicosis: diagnosis and treatment. Indian J Dermatol Venereol Leprol. 2008;74:571–81.PubMedCrossRef
16.
Zurück zum Zitat Mackie I, Langley K, Chitolie A, et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost. 2013;109:488–96.PubMedCrossRef Mackie I, Langley K, Chitolie A, et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost. 2013;109:488–96.PubMedCrossRef
18.
Zurück zum Zitat Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106:922–4.PubMedCrossRef Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106:922–4.PubMedCrossRef
19.
Zurück zum Zitat Elias JE, Mackie I, Eapen CE, Chu P, Shaw JC, Elias E. Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency. J Hepatol. 2013;58:827–30.PubMedCrossRef Elias JE, Mackie I, Eapen CE, Chu P, Shaw JC, Elias E. Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency. J Hepatol. 2013;58:827–30.PubMedCrossRef
20.
Zurück zum Zitat La Mura V, Reverter JC, Flores-Arroyo A, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011;60:1133–8.PubMedCrossRef La Mura V, Reverter JC, Flores-Arroyo A, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011;60:1133–8.PubMedCrossRef
21.
Zurück zum Zitat Eapen CE, Elias JE, Mackie I, Elias E. Prognostic significance of von Willebrand factor in cirrhosis: a possible mechanism. Hepatology. 2013;58:1189.PubMedCrossRef Eapen CE, Elias JE, Mackie I, Elias E. Prognostic significance of von Willebrand factor in cirrhosis: a possible mechanism. Hepatology. 2013;58:1189.PubMedCrossRef
22.
Zurück zum Zitat Poordad F. Thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:5–11.PubMedCrossRef Poordad F. Thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:5–11.PubMedCrossRef
23.
Zurück zum Zitat Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247–50.PubMedCrossRef Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247–50.PubMedCrossRef
24.
Zurück zum Zitat Eapen CE, Nightingale P, Hubscher SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci. 2011;56:227–35.PubMedCrossRef Eapen CE, Nightingale P, Hubscher SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci. 2011;56:227–35.PubMedCrossRef
25.
Zurück zum Zitat Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100–6.PubMedCrossRef Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104:100–6.PubMedCrossRef
26.
Zurück zum Zitat Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 2008;6:1233–5.PubMedCentralPubMedCrossRef Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 2008;6:1233–5.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Manavalan JS, Hernandez L, Shah JG, et al. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010;71:50–7.PubMedCrossRef Manavalan JS, Hernandez L, Shah JG, et al. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010;71:50–7.PubMedCrossRef
28.
Zurück zum Zitat Kumar P, Kumar M, Ramanathan AL, Tsujimura M. Tracing the factors responsible for arsenic enrichment in groundwater of the middle Gangetic Plain, India: a source identification perspective. Environ Geochem Health. 2010;32:129–46.PubMedCrossRef Kumar P, Kumar M, Ramanathan AL, Tsujimura M. Tracing the factors responsible for arsenic enrichment in groundwater of the middle Gangetic Plain, India: a source identification perspective. Environ Geochem Health. 2010;32:129–46.PubMedCrossRef
29.
Zurück zum Zitat Kao YH, Yu CL, Chang LW, Yu HS. Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro. Chem Res Toxicol. 2003;16:460–8.PubMedCrossRef Kao YH, Yu CL, Chang LW, Yu HS. Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro. Chem Res Toxicol. 2003;16:460–8.PubMedCrossRef
31.
Zurück zum Zitat Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631–40.PubMedCrossRef Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631–40.PubMedCrossRef
Metadaten
Titel
ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension
verfasst von
Ashish Goel
P. L. Alagammai
Sukesh C. Nair
Ian Mackie
Banumathi Ramakrishna
Jayaprakash Muliyil
Shyamkumar N. Keshava
C. E. Eapen
Elwyn Elias
Publikationsdatum
01.07.2014
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 4/2014
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-014-0460-4

Weitere Artikel der Ausgabe 4/2014

Indian Journal of Gastroenterology 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.